WITNESSES THAT WHEREAS. InNexus holds the patent for the next-generation technology platform for enhancement of monoclonal antibodies known as SuperAntibody Technology or "SAT";
Appears in 5 contracts
Samples: Development and License Agreement (Innexus Biotechnology Inc), Development and License Agreement (Innexus Biotechnology Inc), Development and License Agreement (Innexus Biotechnology Inc)